Breakthrough T1D Heads, Virtually, to ADA’s 81st Scientific Sessions
At the ADA's 81st Scientific Sessions, healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world.
T1D Doesn’t Discriminate: Know Your Risk with T1Detect
How Breakthrough T1D’s screening education and awareness program can help address health disparities experienced by underserved members of the T1D community.
Just in Time for Father’s Day: Husband, Dad of T1D Family Shares His Experiences
Peterson Cilaire, husband and father of a T1D family, on loving someone who lives with T1D, learning to manage T1D and the importance of fathers and husbands.
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for at-risk individuals.
Advancing Cures with Type 1 Diabetes Clinical Trials
May 20 is Clinical Trials Day, a day to raise awareness of clinical research and the people around the world who take part in trials.
50+ Years with Type 1: An Interview with Dr. George King
I got the privilege of interviewing George King, M.D., whose research is on diabetes complications. Breakthrough T1D has funded him since he was early in his career.
Bigfoot Is Real—and Received FDA Clearance
The Bigfoot Unity™ Diabetes Management by Bigfoot Biomedical received FDA clearance for individuals 12 and older.
At 37, I’m Fighting to Save my Eyesight
At the age of 37, I’m fighting to save my eyesight, a complication of type 1. People are also at risk of developing kidney, heart, and nerve diseases.
National DNA Day!
Aaron Michels, M.D., discovered that methyldopa—a therapy that has been used for 50 years to treat high blood pressure—may have a role in delaying T1D.
FDA Breakthrough Therapy Designation for TTP399—A Potential First-in-Class Adjunct Therapy in T1D
The FDA granted Breakthrough Therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for T1D.
